Maghsoud Dariani - Lobe Sciences Chief Officer

LOBEF Stock  USD 0.02  0.02  895.24%   

Insider

Maghsoud Dariani is Chief Officer of Lobe Sciences
Age 70
Webhttps://www.lobesciences.com

Lobe Sciences Management Efficiency

The company has return on total asset (ROA) of (0.6505) % which means that it has lost $0.6505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.7981) %, meaning that it generated substantial loss on money invested by shareholders. Lobe Sciences' management efficiency ratios could be used to measure how well Lobe Sciences manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Robin DebiaseAscend Wellness Holdings
52
Kevin PittsGrey Cloak Tech
63
Sonny NewmanC21 Investments
N/A
Brian MiesieskiAscend Wellness Holdings
N/A
Robert MaddenGrey Cloak Tech
51
Francis PerulloAscend Wellness Holdings
46
Roman NemchenkoAscend Wellness Holdings
N/A
Abner KurtinAscend Wellness Holdings
56
Christopher MelilloAscend Wellness Holdings
49
Eric ShoemakerC21 Investments
N/A
David GacomAscend Wellness Holdings
N/A
Rebecca BScAscend Wellness Holdings
N/A
Scott LandersGrey Cloak Tech
N/A
Daniel NevilleAscend Wellness Holdings
37
Jason LiottaAscend Wellness Holdings
N/A
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences is traded on OTC Exchange in the United States. Lobe Sciences [LOBEF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Lobe Sciences Management Team

Elected by the shareholders, the Lobe Sciences' board of directors comprises two types of representatives: Lobe Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lobe. The board's role is to monitor Lobe Sciences' management team and ensure that shareholders' interests are well served. Lobe Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lobe Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Philip Young, Corp CEO
Brian Zasitko, Chief Officer
Maghsoud Dariani, Chief Officer

Lobe Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Lobe Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Lobe OTC Stock

Lobe Sciences financial ratios help investors to determine whether Lobe OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lobe with respect to the benefits of owning Lobe Sciences security.